Browsing Tag
Enicepatide
1 post
Roche’s enicepatide delivers 15.5% weight loss in type 2 diabetes Phase II trial
The once-weekly GLP-1 and GIP medicine also brought blood sugar into the normal range for 62% of patients at its highest dose, supporting plans for broader Phase III development in 2027.